Treatment options expanded
With a highly favourable safety profile1,2, Flow provides a convenient at-home treatment option for patients. Clinicians benefit from real-time remote monitoring, which offers insights into adherence and treatment response and supports more informed clinical decisions.
Indication and mechanism of action
Flow is a class IIa medical device certified for the treatment of unipolar major depressive disorder (MDD) in adults, either as monotherapy or as an adjunct with antidepressants and psychological therapies.
The Flow headset delivers a gentle 2mA electric current (transcranial Direct Current Stimulation, tDCS) to the left dorsolateral prefrontal cortex. This region is crucial for emotional regulation and is often hypoactive in individuals with depression. tDCS enhances neuronal activity in this area, counteracting hypoactivity, improving mood and emotional regulation.
Track and optimise patient care with the Flow Clinician Platform
Effortlessly review your patients’ adherence and progress with Flow’s Clinician Platform. Accessible anytime, anywhere through a secure web browser, this platform aggregates data including weekly MADRS-s scores and daily stimulation tracking. With these insights, you can monitor patient response, ensure treatment adherence, and easily customise individual treatment schedules to help optimise patient outcomes.
What this means for clinics
New pathways to remission
Flow fills a long-standing gap by providing an additional effective treatment option2 that can be used as a standalone or augmented to your patients' current treatment plans1,2.
Patients stay engaged, results follow
Flow delivers a treatment experience that patients actively embrace, leading to higher adherence and better outcomes. Average adherence rate in the first 6 weeks is 78%3.
Convenience and ease of use for all
Designed to be used at home, Flow has built-in onboarding for patients and real-time insights for clinicians. Ensuring a smooth experience and a hassle-free addition to your treatment protocols.
The Flow Treatment Schedule
The standard Flow treatment is split into 2 phases - Activation and Strengthening.
Each session (termed stimulation) is 30 minutes long. Patients complete a MADRS-s survey at the beginning of each week to monitor progress.
Flow is recommended for 6-12 months of use pending risk of relapse.
Expected results with Flow
Flow uses the MADRS-s questionnaire to assess depression symptom severity and corresponding fluctuations throughout the treatment. On average, the majority of Flow headset users see significant results within 4 to 6 weeks of treatment1. In the EMPOWER randomised control trial, the average reduction in MADRS was 12.4 points in 10 weeks2.
Supporting patients with Flow
We offer a comprehensive range of resources to support you and your patients in adopting Flow tDCS treatment. From educational videos explaining tDCS, to detailed leaflets about the Flow treatment, on-demand clinician training, and additional CPD opportunities from our dedicated clinical team, we ensure you have everything you need to confidently introduce Flow. Whether it's patient education or professional development, we're here to provide expert support every step of the way.
Experience Flow in Your Practice
As neuromodulation continues to gain traction, we understand the need for hands-on experience. That’s why we offer complimentary training, continuous clinical support, and access to a demo device, so you can explore the benefits of Flow firsthand. Our mission is to expand access to proven mental health treatments, enabling clinicians to provide cutting-edge care that improves patient choice and outcomes.
See how Flow can become part of your treatment offerings—request a demo and start transforming patient care today.
References:
1. Data on file. Flow Neuroscience Real-world reports.
2. Woodham, R. D. et al. (2023). bioRxiv. PREPRINT.
3. Data on file. Flow Neuroscience Real-world reports; NHS pilot site data.